Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Labeling For Optimer's Dificid Includes Data On Ability To Sustain Cure Post-Treatment

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves the macrolide antibacterial for treatment of Clostridium difficile-associated diarrhea.

You may also be interested in...



Optimer Is Up For Sale And Could Attract Hospital-Focused Suitors

The antibiotic company announced it is reviewing strategic options and that CEO Pedro Lichtinger has been replaced by Chairman Henry McKinnell. Hospital-based companies looking to beef up their portfolios with a commercial asset could drive a competitive process.

Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value

Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.

Will New Antibiotic Incentives GAIN Investors’ Backing?

The GAIN Act is intended to spur development of new antibiotics, but incentives like extended market exclusivity and priority review, while important benefits, may not be enough to get investors off the sidelines.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel